Advances in pediatric nonalcoholic fatty liver disease

Pediatric Clinics of North America

Volumn 58, Issue 6, 2011, Pages 1375-1392

  Mencin, Ali A ^a   Lavine, Joel E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Metabolic syndrome; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Obesity; Pediatric; PNPLA3

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CYTOKERATIN 18; DOCOSAHEXAENOIC ACID; FATTY ACID; FRUCTOSE; HYALURONIC ACID; LEPTIN; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADIPONUTRIN GENE; AEROBIC EXERCISE; APOLIPOPROTEIN C3 GENE; CALORIC RESTRICTION; CARBOHYDRATE INTAKE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG SAFETY; ELASTOGRAPHY; ETHNICITY; GENE; GENETIC ASSOCIATION; HEPATITIS; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OVERNUTRITION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; COMORBIDITY; DIAGNOSTIC IMAGING; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; OBESITY; PREVALENCE; UNITED STATES; WEIGHT LOSS;

EID: 81255211552     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.09.005     Document Type: Review

References (130)

1. Schwimmer J.B., Deutsch R., Kahen T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388.
2. Centers for Disease Control and Prevention (CDC) Vital signs: state-specific obesity prevalence among adults -- United States, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:951.
3. Janssen I., Katzmarzyk P.T., Boyce W.F., et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. Obes Rev 2005, 6:123.
4. Ji C.Y. The prevalence of childhood overweight/obesity and the epidemic changes in 1985-2000 for Chinese school-age children and adolescents. Obes Rev 2008, 9(Suppl 1):78.
5. Matthiessen J., Velsing Groth M., Fagt S., et al. Prevalence and trends in overweight and obesity among children and adolescents in Denmark. Scand J Public Health 2008, 36:153.
6. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303:242.
7. Park H.S., Han J.H., Choi K.M., et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005, 82:1046.
8. Roberts E.A. Non-alcoholic fatty liver disease (NAFLD) in children. Front Biosci 2005, 10:2306.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221.
10. Schwimmer J.B., Dunn W., Norman G.J., et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010, 138:1357.
11. Manco M., Marcellini M., Devito R., et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond) 2008, 32:381.
12. Rodriguez G., Gallego S., Breidenassel C., et al. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents?. Nutr Hosp 2010, 25:712.
13. Fraser A., Longnecker M.P., Lawlor D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007, 133:1814.
14. Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011, 300:G697.
15. Manco M., Bedogni G., Marcellini M., et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008, 57:1283.
16. Wiegand S., Keller K.M., Robl M., et al. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16 390 overweight or obese children and adolescents. Int J Obes (Lond) 2010, 34(10):1468-1474.
17. Chitturi S., Wong V.W., Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011, 26(Suppl 1):163.
18. Barshop N.J., Francis C.S., Schwimmer J.B., et al. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. Ped Health 2009, 3:271.
19. Louthan M.V., Theriot J.A., Zimmerman E., et al. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 2005, 41:426.
20. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006, 103:18273.
21. Schwimmer J.B., McGreal N., Deutsch R., et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005, 115:e561.
22. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42:641.
23. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538.
24. Argo C.K., Northup P.G., Al-Osaimi A.M., et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51:371.
25. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972.
26. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820.
27. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26:2183.
28. Kistler K.D., Molleston J., Unalp A., et al. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010, 31:396.
29. Argo C.K., Caldwell S.H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009, 13:511.
30. Schwimmer J.B., Pardee P.E., Lavine J.E., et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008, 118:277.
31. Caserta C.A., Pendino G.M., Amante A., et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol 2010, 171:1195.
32. Demircioglu F., Kocyigit A., Arslan N., et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008, 47:68.
33. Pacifico L., Cantisani V., Ricci P., et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008, 63:423.
34. Pacifico L., Anania C., Martino F., et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1643.
35. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:195.
36. Wong V.W., Wong G.L., Choi P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2011, 59:969.
37. Carter-Kent C., Yerian L.M., Brunt E.M., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009, 50:1113.
38. Chen J., Talwalkar J.A., Yin M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011, 259:749.
39. Schwenzer N.F., Springer F., Schraml C., et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433.
40. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585.
41. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454.
42. Yoneda M., Mawatari H., Fujita K., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008, 40:371.
43. Nobili V., Vizzutti F., Arena U., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48:442.
44. Miller M.H., Ferguson M.A., Dillon J.F. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 2011, 31:461.
45. Wieckowska A., McCullough A.J., Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582.
46. Guha I.N., Parkes J., Roderick P., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455.
47. Nobili V., Parkes J., Bottazzo G., et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009, 136:160.
48. Alkhouri N., Carter-Kent C., Lopez R., et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol 2011, 9(2):150-155.
49. Maffeis C., Banzato C., Rigotti F., et al. Biochemical parameters and anthropometry predict NAFLD in obese children. J Pediatr Gastroenterol Nutr 2011, [Epub ahead of print].
50. Shah A.G., Lydecker A., Murray K., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104.
51. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072.
52. Day C.P., James O.F. Steatohepatitis: a tale of two " hits" ?. Gastroenterology 1998, 114:842.
53. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836.
54. Larter C.Z., Chitturi S., Heydet D., et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672.
55. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519.
56. Hu F.B., Malik V.S. Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. Physiol Behav 2010, 100:47.
57. Stanhope K.L., Schwarz J.M., Keim N.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009, 119:1322.
58. Nielsen S.J., Popkin B.M. Changes in beverage intake between 1977 and 2001. Am J Prev Med 2004, 27:205.
59. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961.
60. Abid A., Taha O., Nseir W., et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009, 51:918.
61. Assy N., Nasser G., Kamayse I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008, 22:811.
62. Vos M.B., Ryan C., Patricia B., et al. Correlation of vitamin E, uric acid and diet composition with histologic features of pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011, [Epub ahead of print].
63. Kohli R., Kirby M., Xanthakos S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934.
64. Funaki M. Saturated fatty acids and insulin resistance. J Med Invest 2009, 56:88.
65. Micha R., Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 2009, 5:335.
66. Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010, 26:160.
67. Obara N., Fukushima K., Ueno Y., et al. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol 2010, 53:326.
68. Tetri L.H., Basaranoglu M., Brunt E.M., et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295:G987.
69. Wang D., Wei Y., Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147:943.
70. Vega G.L., Chandalia M., Szczepaniak L.S., et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007, 46:716.
71. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343.
72. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118:2992.
73. Hosogai N., Fukuhara A., Oshima K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901.
74. Ye J., Gao Z., Yin J., et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118.
75. Turkay C., Ozol D., Kasapoglu B., et al. Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care 2011, [Epub ahead of print].
76. Polyzos S.A., Kountouras J., Zavos C., et al. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol 2010, 45:50.
77. Choi S.S., Syn W.K., Karaca G.F., et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010, 285:36551.
78. De Minicis S., Seki E., Oesterreicher C., et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology 2008, 48:2016.
79. Wang S.N., Lee K.T., Ker C.G. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010, 16:5801.
80. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010, 28:179.
81. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79.
82. Buechler C., Wanninger J., Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011, 17:2801.
83. Polyzos S.A., Kountouras J., Zavos C., et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010, 12:365.
84. Xu A., Wang Y., Keshaw H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91.
85. Miller R.A., Chu Q., Le Lay J., et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 2011, 121:2518.
86. Mandal P., Pratt B.T., Barnes M., et al. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biol Chem 2011, 286:13460.
87. Pisto P., Ukkola O., Santaniemi M., et al. Plasma adiponectin-an independent indicator of liver fat accumulation. Metabolism 2011, [Epub ahead of print].
88. Higuchi N., Kato M., Shundo Y., et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 2008, 38:1122.
89. Tsochatzis E.A., Papatheodoridis G.V., Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009, 2009:831670.
90. Wanless I.R., Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004, 24:99.
91. Choi S.S., Diehl A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008, 19:295.
92. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366.
93. Monetti M., Levin M.C., Watt M.J., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007, 6:69.
94. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774.
95. Witek R.P., Stone W.C., Karaca F.G., et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50:1421.
96. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209.
97. Tilg H., Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care 2010, 13:391.
98. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461.
99. Romeo S., Sentinelli F., Cambuli V.M., et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010, 53:335.
100. Santoro N., Kursawe R., D'Adamo E., et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010, 52:1281.
101. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894.
102. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883.
103. Stickel F., Buch S., Lau K., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011, 53:86.
104. Trepo E., Gustot T., Degre D., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011, 55(4):906.
105. Wilson P.A., Gardner S.D., Lambie N.M., et al. Characterization of the human patatin-like phospholipase family. J Lipid Res 2006, 47:1940.
106. Rae-Whitcombe S.M., Kennedy D., Voyles M., et al. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochem Biophys Res Commun 2010, 402:767.
107. Huang Y., He S., Li J.Z., et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010, 107:7892.
108. Qiao A., Liang J., Ke Y., et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011, 54(2):509-521.
109. Goran M.I., Walker R., Le K.A., et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010, 59:3127.
110. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.
111. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362:1082.
112. Kozlitina J., Boerwinkle E., Cohen J.C., et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467.
113. Valenti L., Nobili V., Al-Serri A. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with non-alcoholic fatty liver. J Hepatol 2011, [Epub ahead of print].
114. Romero-Gomez M. APOC3 polymorphisms and non-alcoholic fatty liver disease: resolving some doubts and raising others. J Hepatol 2011, [Epub ahead of print].
115. Sato F., Tamura Y., Watada H., et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007, 92:3326.
116. Musso G., Gambino R., Cassader M., et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79.
117. Torres D.M., Harrison S.A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134:1682.
118. Nobili V., Marcellini M., Devito R., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44:458.
119. Gronbaek H., Lange A., Birkebaek N.H., et al. Effect of a 10-week weight-loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2011, [Epub ahead of print].
120. Kistler K.D., Brunt E.M., Clark J.M., et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011, 106:460.
121. Barlow S.E. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120(Suppl 4):S164.
122. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675.
123. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659.
124. Nobili V., Bedogni G., Alisi A., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011, 96:350.
125. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143.
126. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:194.
127. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368.
128. Mattar S.G., Velcu L.M., Rabinovitz M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005, 242:610.
129. Pardee P.E., Lavine J.E., Schwimmer J.B. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009, 18:144.
130. Weiner R.A. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010, 28:274.